Thursday, September 30, 2010

YRCW YRC Worldwide Hits The Skids, Bankruptcy Next?

Today YRC Worldwide hit the skids as share volume spiked and price dropped. I have noticed YRCW over the last few months as the company warned about its mounting debts. It looks like YRCW is about to go the way of Blockbuster, bankruptcy! In many cases shareholders of bankrupt companies get nothing, as seen in many recent mega bankruptcies, like GM General Motors. What's amazing about YRCW at this stage is that there are still analysts willing to offer share price predictions for the common stock.  Listed on Yahoo Finance, the analyst estimate for the share price of YRCW is less than inspiring at just 20 cents.

We are not registered  investment advisers, always consult one prior to making an investment.

Are you tired of the same old promises of investor relations firms? They promise the world and deliver almost nothing.  The new approach to investor relations helps companies develop their products, identify new opportunities, and capitalize on them. If you would like to discuss how we can help your company please visit the about us section.

Take caution when considering a penny stock as an investment! Make sure to contact a registered investment adviser!

Tuesday, September 28, 2010

Pacific Ethanol Signs Over 20% of Facilities for $53 Million

Is Pacific Ethanol foolish for taking on new debt or are they preparing for the loss of six billion in subsidies set to expire in December?  The blenders credit, and another which limits competition from imports. A similar scenario played out last year when a biodiesel subsidies were allowed to expire and were not renewed.

"Pacific Ethanol, Inc. (PEI) (Nasdaq:PEIX), the leading West Coast marketer and producer of low-carbon renewable fuels, announced today several transactions intended to further improve the company's balance sheet and position the company for continued growth in the ethanol industry. On September 27, 2010, PEI entered into agreements to issue senior convertible notes (Notes) in the aggregate principal amount of $35.0 million to institutional investors, which agreements are expected to close on or prior to October 11, 2010. In addition, on September 27, 2010, PEI signed an agreement to sell its minority ownership interest in Front Range Energy, LLC for $18.5 million in cash that is expected to close coincident with the closing of the issuance of the Notes. Total gross proceeds from these two transactions are expected to be $53.5 million. On September 28, 2010, PEI entered into agreements to purchase for $23.3 million a 20% ownership interest in New PE Holdco LLC (New PEH), which is the owner of PEI's previously-owned four ethanol production facilities. As a result, PEI will hold the largest equity ownership position in New PEH. Further, PEI intends to retire $17.0 million in corporate debt, accrued interest and fees owed to Lyles United LLC and Lyles Mechanical Co. (Lyles). The balance of the proceeds is expected to pay transaction fees and to provide approximately $10.0 million of cash reserves to PEI's balance sheet."

Should an IR firm be focused on selling investors, or  product? Our system helps CEOs sell their products and become profitable. Give us a call and we will help determine if your company fits our module.

We are not registered investment advisors. Always contact a registered investment advisor prior to making any investment. Penny stock investments generally result in the entire loss of investment.

Monday, September 20, 2010

ACTC Stock Patent Ignites Interest

On September 14 Advanced Cell Technology released new concerning their Stem Cell-Derived RPE Cells to Treat Eye Disorders. The company reports their patent covers 41 claims covering Stargardt’s disease, retinitis pigmentosa, and macular degeneration.

“We believe that these patents are especially important as they extend the company’s patent coverage of the scalable manufacturing of human RPE cells for therapeutic use, which are core to our technology and product portfolio,” continued Mr. Caldwell. “This IP further expands our patent estate with respect to protecting the use of RPE cells in a wide range of treatments, offering additional validation of the strength and breadth of our patent portfolio. This development also dovetails nicely with the prospect of initiating our human clinical trial for our RPE program. We are optimistic that the methods-of-treatments and the culturing processes covered by these two new patents, along with the Company’s proprietary detection technique for final product release, will establish a formidable barrier to entry for any potential competitors. Once we have begun to treat Stargardt patients, we plan to initiate another clinical trial relating to the use of RPE cells in the treatment of dry Age-Related Macular Degeneration (AMD). At present there is no approved treatment for dry AMD, despite the fact that it represents a $20-30 billion potential market.”

Penny Markets contributers are not registered investment advisors. Prior to any investment please consult an investment advisor. Investment in pennystocks can, and often does result in total loss of investment.

Have you considered the alternative to traditional investor relations? Alternative investor relations has evolved to assist corporations drive sales and increase earnings. Visit the investor relations page to find out more! 

Connect with other ACTC investors on the ACTC investors social network